"End-stage" pulmonary fibrosis in sarcoidosis

Mount Sinai Journal of Medicine

Volumn 76, Issue 1, 2009, Pages 30-36

  Teirstein, Alvin T ^a   Morgenthau, Adam S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Airways obstruction; Bullae; Fibrosis; Gallium and PET scans; Hilar retraction; Pulmonary hypertension; Right heart failure; Tented diaphragm

Indexed keywords

BOSENTAN; CORTICOSTEROID; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; PREDNISONE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ARTICLE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE EXACERBATION; DIURESIS; DYSPNEA; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEART FAILURE; HUMAN; IMMUNOPATHOGENESIS; LUNG FIBROSIS; LUNG FUNCTION; LUNG INFILTRATE; LUNG LAVAGE; LUNG PARENCHYMA; OXYGEN THERAPY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SARCOIDOSIS; TH1 CELL; TH2 CELL; THORAX RADIOGRAPHY; CLINICAL TRIAL; EPIDEMIOLOGY; GENETICS; LUNG FUNCTION TEST;

CAUSALITY; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS, PULMONARY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 66149089625     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20090     Document Type: Article

References (33)

1. Siltzbach LE. Sarcoidosis: clinical features and management. Med Clin North Am 1967; 51: 483-502.
2. Scadding JG. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years' observation. Br Med J 1961; 2: 1165-1172.
3. Nunes H, Brillet P, Valeyre D, et al. Imaging in sarcoidosis. Semin Respir Crit Care Med 2007; 28: 102-120.
4. Baughman RP, Teirstein AS, Judson MA, et al., for the ACCESS Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889.
5. Judson MA, Baughman RP, Thompson BW, et al., for the ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 204-211.
6. Longcope WT, Freiman DG. A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from the Johns Hopkins Hospital and Massachusetts General Hospital. Medicine 1952; 31: 1-132.
7. Rosen Y, Vuletin JC, Pertschuk LP, Silverstein E. Sarcoidosis: from the pathologist's vantage point. Pathol Annu 1979; 14: 405-439.
8. Petkova DK, Clelland CA, Ronan JE, et al. Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis. Histopathology 2003; 43: 381-386.
9. Hill MR, Papafili A, Booth H, et al. Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis. Am J Respir Crit Care Med 2006; 174: 915-922.
10. Kruit A, Grutters JC, Ruven HJ, et al. Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest 2006; 129: 1584-1591.
11. Jonth AC, Silveira L, Fingerlin TE, et al., for the ACCESS Group. TGF-beta 1 variants in chronic beryllium disease and sarcoidosis. J Immunol 2007; 179: 4255-4262.
12. Markart P, Luboeinski T, Korfei M, et al. Alveolar oxidative stress is associated with elevated levels of non-enzymatic low-molecular-weight antioxidants in patients with different forms of chronic fibrosing interstitial lung diseases. Antioxid Redox Signal 2008; doi:// 10.1089/ARS.2008.2105. Available at: http://www.liebertonline.com.
13. Kunkel SL, Chensue SW, Lukacs N, Hogaboam C. Cytokine phenotypes serve as a paradigms for experimental immune-mediated lung diseases and remodeling. Am J Respir Cell Mol Biol 2003; 29: S63-S66.
14. Moller DR. Pulmonary fibrosis of sarcoidosis: new approaches, old ideas. Am J Respir Cell Mol Biol 2003; 29: S37-S41.
15. Sugiyama K, Mukae H, Ishii H, et al. Elevated levels of interferon gamma-inducible protein-10 and epithelial neutrophil-activating peptide-78 in patients with pulmonary sarcoidosis. Respirology 2006; 11: 708-714.
16. Agostini C, Cabrelle A, Calabrese F, et al. Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am J Respir Crit Care Med 2005; 172: 1290-1298.
17. Katoh S, Fukushima K, Matsumoto N, et al. Accumulation of CXCR3-expressing eosinophils and increased concentration of its ligands (IP10 and Mig) in bronchoalveolar lavage fluid of patients with chronic eosinophilic pneumonia. Int Arch Allergy Immunol 2005; 137: 229-235.
18. Sekiya M, Ohwada A, Miura K, et al. Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 2003; 181: 259-265.
19. Miller A, Chaung M, Teirstein AS, Siltzbach LE. Pulmonary function in stage I and II pulmonary sarcoidosis. Ann N Y Acad Sci 1976; 278: 292-300.
20. Muller NL, Kullnig P, Miller RR. The CT findings of pulmonary sarcoidosis: analysis of 25 patients. AJR Am J Roentgenol 1989; 152: 1179-1182.
21. Mana J, Teirstein AS, Mendelson DS, et al. Excessive thoracic computed tomographic scanning in sarcoidosis. Thorax 1995; 50: 1264-1266.
22. Davies CW, Tasker AD, Padley SP, et al. Air trapping in sarcoidosis on computed tomography: correlation with lung function. Clin Radiol 2000; 55: 217-221.
23. Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 2000; 174: 1751-1757.
24. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; 18: CD001114.
25. Thomas KW, Hunninghake GW. Sarcoidosis. JAMA 2003; 289: 3300-3303.
26. Selroos O. Value of biochemical markers in serum for determination of disease activity in sarcoidosis. Sarcoidosis 1984; 1: 45-49.
27. Lieberman J, Nosal A, Schlessner A, Sastre-Foken A. Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis 1979; 120: 329-335.
28. NIH conference. Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes. Ann Intern Med 1981; 94: 73-94.
29. Lynch JP III. Computed tomographic scanning in sarcoidosis. Semin Respir Crit Care Med 2003; 24: 393-418.
30. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-1953.
31. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128: 1483-1489.
32. Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration 2008; 75: 211-214.
33. Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122: 233-238.